Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 2, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

November 30, 2016

Conditions
HIV-1 Infection
Interventions
DRUG

Isotretinoin

Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.

Trial Locations (15)

14642

31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester

27401

3203 Greensboro CRS, Greensboro

27516

3201 Chapel Hill CRS, Chapel Hill

35294

31788 Alabama CRS, Birmingham

37204

3652 Vanderbilt Therapeutics (VT) CRS, Nashville

63110

2101 Washington University Therapeutics (WT) CRS, St Louis

77030

31473 Houston AIDS Research Team (HART) CRS, Houston

90035

601 University of California, Los Angeles CARE Center CRS, Los Angeles

94110

801 University of California, San Francisco HIV/AIDS CRS, San Francisco

02114

101 Massachusetts General Hospital (MGH) CRS, Boston

02115

107 Brigham and Women's Hosp. ACTG CRS, Boston

07103

31786 New Jersey Medical School Clinical Research Center CRS, Newark

45267-0405

2401 Cincinnati CRS, Cincinnati

02906

2951 The Miriam Hospital (TMH) ACTG CRS, Providence

00931

5401 Puerto Rico AIDS Clinical Trials Unit CRS, San Juan

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT01969058 - Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery | Biotech Hunter | Biotech Hunter